TR200500108T2 - Kanser Hücresi Gelişiminin İnhibe Edilmesinde Üreaz Kullanımı - Google Patents
Kanser Hücresi Gelişiminin İnhibe Edilmesinde Üreaz KullanımıInfo
- Publication number
- TR200500108T2 TR200500108T2 TR2005/00108T TR200500108T TR200500108T2 TR 200500108 T2 TR200500108 T2 TR 200500108T2 TR 2005/00108 T TR2005/00108 T TR 2005/00108T TR 200500108 T TR200500108 T TR 200500108T TR 200500108 T2 TR200500108 T2 TR 200500108T2
- Authority
- TR
- Turkey
- Prior art keywords
- patient
- cancer cell
- urease
- inhibiting cancer
- cell development
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Memeli bir hastada kanser hücresi gelisiminin inhibe edilmesinde kullanilmasi öngörülen farmasötik bir bilesim açiklanmaktadir. Bilesim, üreaz enzimini ve onunla iliskili olarak, bilesim hastaya uygulandiginda enzimin kanser hücrelerine sevkedilme düzeyini arttirmakta etkili olan kimyasal bir antiteyi içermektedir. ayrica, zayif bazik antitümör bilesiklerinin etkinliligini arttirma yöntemi, bir hastada kati tümörün varligi, boyutu ve konumunu degerlendirme yöntemi ve bir hastada kanserin tedavi edilmesi için bir gen tedavisi bilesimi açiklanmaktadir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39724402P | 2002-07-18 | 2002-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200500108T2 true TR200500108T2 (tr) | 2005-04-21 |
Family
ID=30771022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2005/00108T TR200500108T2 (tr) | 2002-07-18 | 2003-07-16 | Kanser Hücresi Gelişiminin İnhibe Edilmesinde Üreaz Kullanımı |
Country Status (23)
Country | Link |
---|---|
US (1) | US7211250B2 (tr) |
EP (2) | EP2324846B1 (tr) |
JP (4) | JP2006501196A (tr) |
KR (2) | KR20050038005A (tr) |
CN (1) | CN100577203C (tr) |
AU (1) | AU2003250658B2 (tr) |
BR (1) | BR0312664A (tr) |
CA (1) | CA2492472C (tr) |
DK (1) | DK1530482T3 (tr) |
ES (1) | ES2443416T3 (tr) |
HK (2) | HK1076739A1 (tr) |
IL (1) | IL166249A (tr) |
MX (1) | MXPA05000778A (tr) |
NO (1) | NO336811B1 (tr) |
NZ (1) | NZ538284A (tr) |
PL (1) | PL217626B1 (tr) |
PT (1) | PT1530482E (tr) |
RU (1) | RU2326691C2 (tr) |
SI (1) | SI1530482T1 (tr) |
TR (1) | TR200500108T2 (tr) |
UA (1) | UA81634C2 (tr) |
WO (1) | WO2004009112A1 (tr) |
ZA (1) | ZA200500423B (tr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7264800B2 (en) * | 2002-07-18 | 2007-09-04 | Helix Biopharma Corporation | Method and composition for inhibiting cancer cell growth |
WO2004023981A2 (en) * | 2002-09-11 | 2004-03-25 | Duke University | Methods and compositions for blood pool identification, drug distribution quantification and drug release verification |
US7769423B2 (en) * | 2002-09-11 | 2010-08-03 | Duke University | MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting |
WO2005040333A2 (en) * | 2003-10-24 | 2005-05-06 | National Research Council Of Canada | Ligand-pseudoreceptor system for generation of adenoviral vectors with altered tropism |
IL182956A0 (en) * | 2007-05-03 | 2008-01-20 | Yeda Res & Dev | Glycan modified soluble receptors and binding proteins and their use |
US8892184B2 (en) | 2010-10-18 | 2014-11-18 | Siemens Medical Solutions Usa, Inc. | Systems and methods for reducing interference in a dual modality imaging system |
CA2908475C (en) * | 2013-04-08 | 2020-09-08 | Helix Biopharma Corp. | Use of antibody-urease conjugates for diagnostic and therapeutic purposes |
BR112017015582A2 (pt) * | 2015-01-23 | 2018-03-13 | Helix Biopharma Corp | conjugados de anticorpo-urease para propósitos terapêuticos |
US10640806B2 (en) | 2016-09-24 | 2020-05-05 | Helix Biopharma Corp. | Restoring function of tumour acidified T cells |
US20180243437A1 (en) * | 2017-01-05 | 2018-08-30 | Heman Lap Man CHAO | Anti-vegfr-2 urease conjugates |
EP4154885A4 (en) * | 2020-05-20 | 2024-06-05 | Medrx Co Ltd | PERCUTANEOUS ABSORPTION TYPE PREPARATION CONTAINING APOMORPHINE |
MX2022015897A (es) * | 2020-06-15 | 2023-01-24 | Kortuc Inc | Sensibilizador para el tratamiento del cancer. |
CN113433087A (zh) * | 2021-06-22 | 2021-09-24 | 中南大学 | 一种尿素浓度快速检测方法及检测传感器和应用 |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4329332A (en) | 1978-07-19 | 1982-05-11 | Patrick Couvreur | Biodegradable submicroscopic particles containing a biologically active substance and compositions containing them |
US4489055A (en) | 1978-07-19 | 1984-12-18 | N.V. Sopar S.A. | Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
FR2504408B1 (fr) | 1981-04-24 | 1986-02-14 | Couvreur Patrick | Procede de preparation de particules submicroscopiques, particules ainsi obtenues et compositions pharmaceutiques les contenant |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
DE3377484D1 (en) | 1982-04-19 | 1988-09-01 | Nissan Motor | Method for controlling reduction ratio of continuously variable transmission with acceleration compensation |
US4824783A (en) | 1983-12-20 | 1989-04-25 | Enichem S.P.A. | Oxidized sulfur derivatives of diaminophosphinyl compounds as urease inhibitors |
US4545985A (en) | 1984-01-26 | 1985-10-08 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services | Pseudomonas exotoxin conjugate immunotoxins |
US4894443A (en) | 1984-02-08 | 1990-01-16 | Cetus Corporation | Toxin conjugates |
US4625014A (en) | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
DE3680924D1 (de) | 1985-01-14 | 1991-09-26 | Neorx Corp | Metall-radionuklid markiertes protein fuer diagnose und therapie. |
US4837380A (en) * | 1985-09-30 | 1989-06-06 | Regents Of University Of California | Liposome-calcitonin preparation |
US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
US4680333A (en) | 1986-04-14 | 1987-07-14 | National Starch And Chemical Corporation | Removable hot melt pressure sensitive adhesive |
US4867962A (en) | 1988-02-26 | 1989-09-19 | Neorx Corporation | Functionally specific antibodies |
CA1340323C (en) | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
FR2637612B1 (fr) | 1988-10-06 | 1993-09-10 | Pasteur Institut | Sequences de nucleotides codant pour une proteine a activite ureasique |
EP0460607A3 (en) * | 1990-06-05 | 1992-04-01 | Bristol-Myers Squibb Company | Novel monoclonal antibody to novel antigen associated with human tumors |
US5298399A (en) | 1990-08-10 | 1994-03-29 | Sapporo Breweries Limited | Gene and process for producing a thermostable urease |
US5140100A (en) | 1990-12-28 | 1992-08-18 | Cedars-Sinai Medical Center | Protein that inhibits production of human choriogonadotropin |
FR2683159B1 (fr) | 1991-10-31 | 1994-02-25 | Coletica | Procede de fabrication de nanocapsules a paroi a base de proteines reticulees; nanocapsules ainsi obtenues et compositions cosmetiques, pharmaceutiques et alimentaires en comportant application. |
US5573934A (en) * | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
WO1993020221A1 (en) * | 1992-04-03 | 1993-10-14 | Young Alexander T | Gene therapy using targeted viral vectors |
US5976535A (en) | 1992-06-09 | 1999-11-02 | Neorx Corporation | Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore |
US6358490B2 (en) | 1992-06-09 | 2002-03-19 | Neorx Corporation | Three-step pretargeting methods and compounds |
US6290962B1 (en) * | 1992-11-03 | 2001-09-18 | Oravax, Inc. | Urease-based vaccine and treatment for helicobacter infection |
GB9300875D0 (en) | 1993-01-18 | 1993-03-10 | Ucb Sa | Nanocapsule containing pharmaceutical compositions |
EP0684814B1 (en) | 1993-02-22 | 1998-06-17 | Alza Corporation | Compositions for oral delivery of active agents |
WO1995014093A1 (en) * | 1993-05-19 | 1995-05-26 | Institut Pasteur | Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions and nucleic acid sequences encoding said polypeptides |
CA2190494C (en) | 1994-05-18 | 2002-05-07 | Michael E. Houston | Heterodimer polypeptide immunogen carrier composition and method |
GB9417873D0 (en) | 1994-09-06 | 1994-10-26 | Sandoz Ltd | Organic compounds |
US5886143A (en) | 1994-12-07 | 1999-03-23 | Neorx Corporation | Hepatic-directed compounds and reagents for preparation thereof |
US6172045B1 (en) | 1994-12-07 | 2001-01-09 | Neorx Corporation | Cluster clearing agents |
FR2732605B1 (fr) * | 1995-04-07 | 1997-05-16 | Pasteur Merieux Serums Vacc | Composition destinee a l'induction d'une reponse immunitaire mucosale |
DE69619683T2 (de) * | 1995-09-06 | 2002-09-26 | Austrian Nordic Biotherapeutic | Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv |
JP2000504670A (ja) | 1996-01-31 | 2000-04-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 腫瘍細胞の成長を抑制する方法 |
WO1997035012A1 (en) | 1996-03-20 | 1997-09-25 | Board Of Regents, The University Of Texas System | Sensitization of her-2/neu overexpressing cancer cells to chemotherapy |
JPH1017492A (ja) * | 1996-07-02 | 1998-01-20 | Fuji Yakuhin Kogyo Kk | 腫瘍細胞増殖抑制剤 |
US5958892A (en) | 1996-07-30 | 1999-09-28 | Board Of Regents, The University Of Texas System | 2-methoxyestradiol-induced apoptosis in cancer cells |
US5750496A (en) * | 1996-08-12 | 1998-05-12 | Utah State University | Method of controlling cryptosporidium infectons using protease inhibitors |
EP0824019B1 (en) * | 1996-08-13 | 2002-11-20 | Quest International B.V. | Inhibition or reduction of oral malodour |
WO1998016201A1 (en) | 1996-10-11 | 1998-04-23 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
CN1181422A (zh) * | 1996-10-31 | 1998-05-13 | 上海市肿瘤研究所 | 与生长因子受体结合的多肽所构建的基因转移载体 |
US6180114B1 (en) | 1996-11-21 | 2001-01-30 | University Of Washington | Therapeutic delivery using compounds self-assembled into high axial ratio microstructures |
US6045774A (en) | 1997-01-10 | 2000-04-04 | Epicyte Pharmaceutical Inc. | J chain polypeptide targeting molecule linked to an imaging agent |
GB9703633D0 (en) * | 1997-02-21 | 1997-04-09 | Imp Cancer Res Tech | Cancer therapy |
US6190923B1 (en) | 1997-09-05 | 2001-02-20 | David K. Johnson | Diethylenetriamine-N,N′,N″-triacetic acid derivatives |
FR2772025B1 (fr) | 1997-12-10 | 2000-03-03 | Guerbet Sa | Chelates metalliques de macrocycles polyaminocarboxyliques et leur application a l'imagerie par resonance magnetique |
US6426086B1 (en) * | 1998-02-03 | 2002-07-30 | The Regents Of The University Of California | pH-sensitive, serum-stable liposomes |
CA2622786A1 (en) * | 1998-10-16 | 2000-04-27 | Naoto Oku | Neovascular-specific peptides |
FR2790405B1 (fr) | 1999-03-02 | 2001-04-20 | Oreal | Nanocapsules a base de polymeres dendritiques |
WO2000052457A1 (en) | 1999-03-02 | 2000-09-08 | Helix Biopharma Corporation | Card-based biosensor device |
US6159443A (en) | 1999-04-29 | 2000-12-12 | Vanderbilt University | X-ray guided drug delivery |
ES2329437T3 (es) * | 1999-06-25 | 2009-11-26 | Genentech, Inc. | Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2. |
US6307372B1 (en) | 1999-11-02 | 2001-10-23 | Glaxo Wellcome, Inc. | Methods for high throughput chemical screening using magnetic resonance imaging |
WO2001037721A2 (en) | 1999-11-22 | 2001-05-31 | The Research Foundation Of State University Of New York | Magnetic nanoparticles for selective therapy |
US20020041898A1 (en) | 2000-01-05 | 2002-04-11 | Unger Evan C. | Novel targeted delivery systems for bioactive agents |
AU2001280105A1 (en) * | 2000-08-22 | 2002-03-04 | Kyowa Hakko Kogyo Co. Ltd. | Methof of regulating apoptosis and apoptosis-regulatory polypeptide |
EP1441766B1 (en) * | 2001-10-16 | 2011-09-14 | MacroGenics West, Inc. | Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof |
-
2003
- 2003-07-16 KR KR1020057000961A patent/KR20050038005A/ko active Search and Examination
- 2003-07-16 RU RU2005104113/15A patent/RU2326691C2/ru active
- 2003-07-16 TR TR2005/00108T patent/TR200500108T2/tr unknown
- 2003-07-16 KR KR1020117022947A patent/KR101352826B1/ko active IP Right Grant
- 2003-07-16 MX MXPA05000778A patent/MXPA05000778A/es active IP Right Grant
- 2003-07-16 CA CA2492472A patent/CA2492472C/en not_active Expired - Lifetime
- 2003-07-16 EP EP10014201.7A patent/EP2324846B1/en not_active Expired - Lifetime
- 2003-07-16 EP EP03764850.8A patent/EP1530482B9/en not_active Expired - Lifetime
- 2003-07-16 AU AU2003250658A patent/AU2003250658B2/en not_active Ceased
- 2003-07-16 SI SI200332335T patent/SI1530482T1/sl unknown
- 2003-07-16 NZ NZ538284A patent/NZ538284A/en not_active IP Right Cessation
- 2003-07-16 PL PL374675A patent/PL217626B1/pl unknown
- 2003-07-16 PT PT37648508T patent/PT1530482E/pt unknown
- 2003-07-16 US US10/621,833 patent/US7211250B2/en active Active
- 2003-07-16 WO PCT/CA2003/001061 patent/WO2004009112A1/en active Application Filing
- 2003-07-16 ES ES03764850.8T patent/ES2443416T3/es not_active Expired - Lifetime
- 2003-07-16 BR BR0312664-1A patent/BR0312664A/pt not_active Application Discontinuation
- 2003-07-16 DK DK03764850.8T patent/DK1530482T3/da active
- 2003-07-16 UA UAA200501034A patent/UA81634C2/ru unknown
- 2003-07-16 CN CN03822307A patent/CN100577203C/zh not_active Expired - Fee Related
- 2003-07-16 JP JP2004522053A patent/JP2006501196A/ja not_active Withdrawn
-
2005
- 2005-01-12 IL IL166249A patent/IL166249A/en active IP Right Grant
- 2005-01-17 ZA ZA200500423A patent/ZA200500423B/xx unknown
- 2005-02-15 NO NO20050793A patent/NO336811B1/no not_active IP Right Cessation
- 2005-10-07 HK HK05108909.8A patent/HK1076739A1/xx not_active IP Right Cessation
- 2005-10-07 HK HK11112705.8A patent/HK1158103A1/xx not_active IP Right Cessation
-
2011
- 2011-07-22 JP JP2011161332A patent/JP5850561B2/ja not_active Expired - Fee Related
-
2013
- 2013-07-16 JP JP2013147555A patent/JP2013213055A/ja not_active Withdrawn
-
2015
- 2015-10-08 JP JP2015199988A patent/JP2016014066A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cohen et al. | Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy | |
TR200500108T2 (tr) | Kanser Hücresi Gelişiminin İnhibe Edilmesinde Üreaz Kullanımı | |
Phillips et al. | Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges | |
Verbeek et al. | O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. | |
Liu et al. | Isocitrate dehydrogenase mutations in glioma: genetics, biochemistry, and clinical indications | |
Durinck et al. | Epigenetic regulation of neuroblastoma development | |
NZ626867A (en) | Compositions and methods for the treatment of infections and tumors | |
MXPA05005923A (es) | Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma. | |
WO2007143752A3 (en) | Targets in breast cancer for prognosis or therapy | |
Sarries et al. | Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer | |
WO2003106974A3 (en) | DIAGNOSIS AND TREATMENT OF CHEMICAL RESISTANT TUMORS | |
NO20074817L (no) | Epidermal vekstfaktorreseptor genkopiantall | |
EP1755659A4 (en) | USE OF ANTI-ALPHA5BETA1 ANTIBODIES TO INHIBIT CANCER CELL PROLIFERATION | |
TR200201089T2 (tr) | Dipiridamol veya mopidamolün fibrine bağlı mikrodolaşım bozukluklarının tedavisi | |
Kovacs | Relevance of positive margins in case of adjuvant therapy of oral cancer | |
Lu et al. | De-ubiquitination of p300 by USP12 Critically Enhances METTL3 Expression and Ang II-induced cardiac hypertrophy | |
EP1377596A4 (en) | USE OF THE TTK FOR DIAGNOSTIC PURPOSES AND AS A THERAPEUTIC TARGET OF CANCER | |
Humeniuk et al. | Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance | |
An et al. | Stimuli‐Responsive PROTACs for Controlled Protein Degradation | |
Saif et al. | Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase–deficient patient treated with capecitabine | |
Gales et al. | In Vivo Study of BPA (boron10-phenilalanine) use in boron neutron capture radiotherapy as an alternative for hepatic cancer treatment | |
Nong et al. | Mechanism and application of nonessential amino acid deprivation associated with tumor therapy | |
MXPA05009715A (es) | Anticuerpo contra antigeno especifico de tumor como objetivo. | |
Gevorkyan et al. | Anticancer efficacy of hydroxyethylthiamine diphosphate in vivo | |
ATE537838T1 (de) | Kombinationstherapie mit kloretazin(tm) |